Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient

Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood‐brain barrier and high risk of relapse. Patients with good performance status, chemo‐sensitive disease, and eligible for autologous stem cell transplant (ASCT) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Camus, Vincent, Dubois, Sydney, Lepretre, Stéphane, Jardin, Fabrice, Tilly, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099056/
https://www.ncbi.nlm.nih.gov/pubmed/30147874
http://dx.doi.org/10.1002/ccr3.1630
_version_ 1783348584448524288
author Camus, Vincent
Dubois, Sydney
Lepretre, Stéphane
Jardin, Fabrice
Tilly, Hervé
author_facet Camus, Vincent
Dubois, Sydney
Lepretre, Stéphane
Jardin, Fabrice
Tilly, Hervé
author_sort Camus, Vincent
collection PubMed
description Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood‐brain barrier and high risk of relapse. Patients with good performance status, chemo‐sensitive disease, and eligible for autologous stem cell transplant (ASCT) may benefit from salvage therapy and therapeutic intensification that may allow long‐term remission.
format Online
Article
Text
id pubmed-6099056
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60990562018-08-24 Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient Camus, Vincent Dubois, Sydney Lepretre, Stéphane Jardin, Fabrice Tilly, Hervé Clin Case Rep Case Reports Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood‐brain barrier and high risk of relapse. Patients with good performance status, chemo‐sensitive disease, and eligible for autologous stem cell transplant (ASCT) may benefit from salvage therapy and therapeutic intensification that may allow long‐term remission. John Wiley and Sons Inc. 2018-06-04 /pmc/articles/PMC6099056/ /pubmed/30147874 http://dx.doi.org/10.1002/ccr3.1630 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Camus, Vincent
Dubois, Sydney
Lepretre, Stéphane
Jardin, Fabrice
Tilly, Hervé
Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title_full Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title_fullStr Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title_full_unstemmed Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title_short Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
title_sort prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099056/
https://www.ncbi.nlm.nih.gov/pubmed/30147874
http://dx.doi.org/10.1002/ccr3.1630
work_keys_str_mv AT camusvincent prolongedthirdcompleteremissionafterbusulfanthiotepaandautologousstemcelltransplantinaprimarycentralnervoussystemlymphomapatient
AT duboissydney prolongedthirdcompleteremissionafterbusulfanthiotepaandautologousstemcelltransplantinaprimarycentralnervoussystemlymphomapatient
AT lepretrestephane prolongedthirdcompleteremissionafterbusulfanthiotepaandautologousstemcelltransplantinaprimarycentralnervoussystemlymphomapatient
AT jardinfabrice prolongedthirdcompleteremissionafterbusulfanthiotepaandautologousstemcelltransplantinaprimarycentralnervoussystemlymphomapatient
AT tillyherve prolongedthirdcompleteremissionafterbusulfanthiotepaandautologousstemcelltransplantinaprimarycentralnervoussystemlymphomapatient

Ejemplares similares